Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Witzig, C. Loprinzi, N. Gonchoroff, H. Reiman, S. Cha, H. Wieand, J. Katzmann, J. Paulsen, C. Moertel (1991)
DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinomaCancer, 68
N. Hole, P. Stern (1990)
Isolation and characterization of 5T4, a tumour‐associated antigenInternational Journal of Cancer, 45
R. Peto, M. Pike, P. Armitage, N. Breslow, D. Cox, S. Howard, N. Mantel, K. McPherson, J. Peto, Peter Smith (1976)
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.British Journal of Cancer, 34
M. Leon, Milena Sant, A. Micheli, Carla Sacchetti, C. Gregorio, R. Fante, G. Zanghieri, G. Melotti, G. Gatta (2008)
Trends in Incidence, Risk Factors, and Survival in Symptomatic Lacunar Stroke in Dijon, France, From 1989 to 2006: A Population-Based StudyStroke, 39
Rupert Turnbull, K. Kyle, Frank Watson, J. Spratt (1968)
Cancer of the colon: The influence of theno‐touch isolation technic on survival ratesCA: A Cancer Journal for Clinicians, 18
J. Krook, C. Moertel, L. Gunderson, H. Wieand, R. Collins, R. Beart, T. Kubista, M. Poon, W. Meyers, J. Mailliard, D. Twito, R. Morton, M. Veeder, T. Witzig, S. Cha, S. Vidyarthi (1991)
Effective surgical adjuvant therapy for high-risk rectal carcinoma.The New England journal of medicine, 324 11
(1989)
Clinical and pathological associations with allelic loss in colorectal carcinoma Cancer of the colon and rectum: consensus statement
(1990)
Immunological distribution of 5T4 antigen in normal and malignant tissues
(1990)
1989 Cancer Facts and Figures
L. Matturri, B. Biondo, F. Uggeri, A. Lavezzi (1991)
Densitometric evaluation of DNA content in colorectal cancer.European journal of cancer, 27 7
E. Fearon, B. Vogelstein (1990)
A genetic model for colorectal tumorigenesisCell, 61
C. Moertel, T. Fleming, J. Macdonald, D. Haller, J. Laurie, P. Goodman, J. Ungerleider, W. Emerson, D. Tormey, J. Glick, M. Veeder, J. Mailliard (1990)
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.The New England journal of medicine, 322 6
H. Tomoda, YOSHlHlRO Kakeji, M. Furusawa (2006)
A Prospective Study
T. Starzyńska, V. Rahi, P. Stern (1992)
The expression of 5T4 antigen in colorectal and gastric carcinoma.British Journal of Cancer, 66
B. Vogelstein, E. Fearon, S. Kern, S. Hamilton, A. Preisinger, Y. Nakamura, Raymond White (1989)
Allelotype of colorectal carcinomas.Science, 244 4901
R. Peto, M. Pike, P. Armitage, N. Breslow, D. Cox, S. Howard, N. Mantel, K. McPherson, J. Peto, Peter Smith (1977)
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.British Journal of Cancer, 35
(1989)
Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and combination of levamisole and fluorouracil
K. Myers, Veena Rahi-Saund, M. Davison, J. Young, Amanada Cheater, P. Stern (1994)
Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein. An antigen associated with metastasis contains leucine-rich repeats.The Journal of biological chemistry, 269 12
C. Dukes (1980)
The classification of cancer of the rectumDiseases of the Colon & Rectum, 23
B. Eisenberg, J. Decosse, F. Harford, Joel Michalek (1982)
Carcinoma of the colon and rectum: The natural history reviewed in 1704 patientsCancer, 49
N. Dubrawsky (1989)
Cancer statisticsCA: A Cancer Journal for Clinicians, 39
M. O’connell, D. Schaid, V. Ganju, J. Cunningham, J. Kovach, S. Thibodeau (1992)
Current status of adjuvant chemotherapy for colorectal cancer: Can molecular markers play a role in predicting prognosis?Cancer, 70
N. Hole, P. Stern (1988)
A 72 kD trophoblast glycoprotein defined by a monoclonal antibody.British Journal of Cancer, 57
The 5T4 oncofetal antigen is a 72 kDa glycoprotein defined by a monoclonal antibody raised against human placental trophoblast and is expressed in many different carcinomas but detected only at low levels in some normal epithelia. Immunohistochemical analysis of the patterns of expression in colorectal carcinomas has indicated a significant association between the presence of the antigen in tumour cells and metastatic spread. The 5T4 antigen phenotype of 72 colorectal cancers has been compared with the clinical outcome of the patients in order to assess its relationship with prognosis. Forty per cent of tumours were 5T4 positive; the remainder were either unlabelled or exhibited stroma-associated labelling only. There was a significant correlation between 5T4 expression in the malignant cells and unfavourable course of disease (P < 0.001). The 5 year survival with 5T4-positive tumours was 22% compared with 75% for patients with 5T4-negative tumours; median survival was 24 versus > 90 months respectively. Stratified analysis showed that 5T4 antigen tumour positivity was acting independently of each of stage, site of tumour, age or sex. There were significant differences in survival for patients with Dukes' B and C stage carcinomas (P = 0.001 and P = 0.034). The results suggest that in colorectal cancer immunohistochemical assessment of 5T4 expression may be useful in identifying patients at high risk for tumour recurrence and for whom additional treatment strategies might be most appropriate.
British Journal of Cancer – Springer Journals
Published: May 1, 1994
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.